Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

A drug delivery system for the prevention of cerebral vasospasm

A technology for cerebral vasospasm and drugs, applied in the field of compound delivery systems, which can solve the problems of lack of effectiveness, time-consuming, side effects, etc.

Inactive Publication Date: 2010-10-27
EDGE THERAPEUTICS
View PDF6 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the treatments described above are expensive, time-consuming, and only partially effective
[0132] Physicians have worked to prevent or reduce the incidence of vasospasm for more than 35 years, with limited success due to side effects or lack of effectiveness of currently used drugs
Without being bound by theory, it is believed that systemic delivery of voltage-gated calcium channel antagonist and endothelin antagonist drugs may result in side effects that counteract the beneficial effect on vasospasm, such as, for example, systemic hypotension and pulmonary edema. local vasodilation, which precludes the use of higher systemic doses

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A drug delivery system for the prevention of cerebral vasospasm
  • A drug delivery system for the prevention of cerebral vasospasm
  • A drug delivery system for the prevention of cerebral vasospasm

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0142] The present invention relates to a delivery system for delivering therapeutic agents to cerebral arteries to prevent or reduce the severity of cerebral vasospasm. More specifically, the present invention relates to delivery systems for the delivery of drugs to cerebral arteries that prevent or reduce the severity of cerebral vasospasm. Unlike previously studied existing therapeutic methods including intravenous and intraarterial drug delivery, the present invention provides a drug delivery system that delivers therapeutic agents to specific regions around cerebral arteries, which achieves local release of the drug and through Reduced delayed cerebral ischemia (DCI) caused by cerebral vasospasm leads to better efficacy. In one aspect, the invention provides the use of a transient receptor potential protein blocker as an active substance that blocks channels that are believed to be alternative pathways that are activated during the development of vasospasm.

[0143] In o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
sizeaaaaaaaaaa
Login to View More

Abstract

The present invention relates to the treatment and prevention of vasospasm. The present invention provides a system for treating a cerebral vasospasm in a human utilizing a pharmaceutical composition and administrating a therapeutically effective amount of the pharmaceutical composition to a predetermined location in close proximity to a cerebral artery within a subarachnoid space, wherein the pharmaceutical composition produces a localized pharmacologic effect thereby treating the cerebral vasospasm.

Description

[0001] cross reference field of invention [0002] The present invention relates to a compound delivery system targeting at least one cerebral artery to prevent and / or reduce the occurrence or severity of cerebral vasospasm, and / or Blockage of at least one of the brain arteries caused by other symptoms such as narrowing of the blood vessels. Background of the invention [0003] The human brain accounts for only about 2% of the total body weight, but receives about 15% of cardiac output, and its oxygen consumption is close to 20% of that of the whole body. These values ​​account for the high metabolic rate and oxygen demand of the brain. These needs are met by a correspondingly high velocity of blood flow per unit of brain weight. Blood circulation to the brain is supplied by the internal carotid and spinal arteries. The total blood flow to the brain is about 750-1000 ml / min; about 350 ml flows through each internal carotid artery and about 100-200 ml flows through the spi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/553
CPCA61K9/0085A61K45/06A61K47/34A61P25/00A61P9/00A61P9/10A61K9/0002A61K9/20A61K31/4178A61K31/4422A61K31/553
Inventor R·骆克·麦克唐纳布赖恩·洛伊特纳
Owner EDGE THERAPEUTICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com